Lymphoma: all 5,624 studies

Page 23 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With LymphomaActive, not recruitingNCT06744075Not applicable
• A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular LymphomaActive, not recruitingNCT06742879
• An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient ProgrammeActive, not recruitingNCT06734078
• A Study of TLN-254 in Participants With Relapsed or Refractory T-cell LymphomaActive, not recruitingNCT06733441Phase 1
• Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide StudyCompletedNCT06714370
• Mediastinal Recurrence of Lympho-proliferative Disorders: a Biopsy is NeededCompletedNCT06714045
• Tazemetostat Plus CHOP in 1L T-cell LymphomaWithdrawnNCT06692452Phase 2
• ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisSuspendedNCT06680661Phase 2
• High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System LymphomaTerminatedNCT06625359Phase 2
• A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06624085Phase 1
• Enhanced Assistance During Radiotherapy for Unmet Essential NeedsCompletedNCT06582849Not applicable
• Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma PatientsCompletedNCT06564259
• To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced TumorsCompletedNCT06558513Phase 1/2
• Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell TherapyActive, not recruitingNCT06552572Phase 2
• A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).Active, not recruitingNCT06550336Phase 2
• A Retrospective Study on Extranodal DLBCLCompletedNCT06549361
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory LymphomaStatus unknownNCT06532643Early Phase 1
• Primary Renal Lymphoma on a 48 Year Old WomanCompletedNCT06525467
• Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With HemoblastosisActive, not recruitingNCT06475820Phase 2/3
• First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)CompletedNCT06454266Phase 2
• CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot TrialCompletedNCT06439420Phase 2
• A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruitingNCT06425302Phase 2
• BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.Active, not recruitingNCT06424379
• Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line TherapyCompletedNCT06422247
• Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced CancerActive, not recruitingNCT06416085Phase 2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingNCT06400225Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingNCT06390865Phase 2
• Retun-to-school Adaptation Program for Children With CancerCompletedNCT06389357Not applicable
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingNCT06385496Phase 2
• EchoTip AcuCore Post-Market Clinical StudyCompletedNCT06358001
• Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaActive, not recruitingNCT06356129Phase 3
• Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHLNo longer availableNCT06331832
• Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell TransplantationActive, not recruitingNCT06328699Not applicable
• Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.CompletedNCT06295211
• PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCLWithdrawnNCT06290622Phase 1
• YASU Research Registry: For Young Adults With CancerTerminatedNCT06275854
• Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.CompletedNCT06271369
• Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2
• Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)CompletedNCT06235047
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnNCT06210750Phase 2
• C752 for Refractory/Relapsed B Cell Non-Hodgkin LymphomaTerminatedNCT06210243Phase 1
• A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWithdrawnNCT06205290Phase 3
• CAREMM-2306: Advanced Immunotherapy vs. Classical ImmunotherapyActive, not recruitingNCT06202885
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaActive, not recruitingNCT06191744Phase 3
• Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin LymphomaCompletedNCT06190457
• AIMN Multicenter Study: Staging of Lymphomas Using PET/CTCompletedNCT06179693
• ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell LymphomaCompletedNCT06149390
• CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell LymphomaActive, not recruitingNCT06149169Phase 2
• A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy AloneWithdrawnNCT06104878
• Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLActive, not recruitingNCT06093841Phase 2
• Study of BEBT-908 in Subjects With Advanced Hematological TumorsCompletedNCT06082596Phase 1
• Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 MaintenanceActive, not recruitingNCT06070961
• Zanubrutinib in Primary Cold Agglutinin DiseaseActive, not recruitingNCT06067048Phase 2
• Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 TherapyActive, not recruitingNCT06049134Phase 4
• A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingNCT06035497Phase 1/2
• Feasibility of an Adapted Sports Program Based on Fencing to Reduce Physical Deconditioning in Adult Hematology PatientsCompletedNCT06026046Not applicable
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
• Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell LymphomasCompletedNCT05991973Phase 2
• Study of Tazemetostat in Lymphoid MalignanciesTerminatedNCT05983965Phase 1
• A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell LymphomaTerminatedNCT05972720Phase 2
• R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell LymphomaWithdrawnNCT05966233Phase 2
• Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLCompletedNCT05958134
• A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaActive, not recruitingNCT05952037Phase 2
• A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
• Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWithdrawnNCT05936229Phase 1/2
• FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaWithdrawnNCT05934097Phase 1
• Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell LymphomaActive, not recruitingNCT05934045
• An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnNCT05929716Phase 2
• Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL StudyCompletedNCT05927558
• Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient SettingsCompletedNCT05918809
• A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Phase 1
• A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedNCT05896163Phase 1/2
• A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab VedotinCompletedNCT05886478
• A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)Active, not recruitingNCT05885464Phase 1/2
• KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical TrialWithdrawnNCT05882305Early Phase 1
• A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.Active, not recruitingNCT05878691Phase 1
• Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnNCT05867030Phase 1
• Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaActive, not recruitingNCT05864742Phase 2
• A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-LymphomaActive, not recruitingNCT05840289
• Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and LymphomasStatus unknownNCT05833984Phase 1/2
• A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical TrialsCompletedNCT05827341
• Skin Barrier and Microbiome of CTCL PatientsCompletedNCT05827107
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.Status unknownNCT05821192Not applicable
• BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell TransplantationCompletedNCT05813132Not applicable
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
• Clinical Trial of Roflumilast Added to Standard ChemoimmunotherapyWithdrawnNCT05796271Phase 1
• Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT05786989Phase 4
• R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05784987Not applicable
• Observational Study of People Living With HIV Treated With CD19-directed CAR T CellCompletedNCT05784415
• Telerehabilitation in Hemato-oncological SurvivorsCompletedNCT05779605Not applicable
• R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaStatus unknownNCT05777369Not applicable
• Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell LymphomaStatus unknownNCT05776407Phase 1/2
• L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLHCompletedNCT05775705Not applicable
• Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid TumorsCompletedNCT05775406Phase 1
• Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell LymphomaStatus unknownNCT05774028Phase 2
• Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)Status unknownNCT05772728Not applicable
• Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's LymphomaStatus unknownNCT05772624Phase 2
• Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell ImmunotherapyCompletedNCT05763563Not applicable

← Lymphoma overview